Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC

NCT04699721 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer Stage II
Non-small Cell Lung Cancer Stage ⅢA
Non-small Cell Lung Cancer Stage IIIB

Interventions

DRUG: nivolumab 4.5mg/kg+Paclitaxel (albumin-bound type) 260mg / m2+ Carboplatin AUC5

Sponsor

Xiangya Hospital of Central South University